172 related articles for article (PubMed ID: 12646281)
1. Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT 2C receptor responsivity.
Bull EJ; Hutson PH; Fone KC
Neuropharmacology; 2003 Mar; 44(4):439-48. PubMed ID: 12646281
[TBL] [Abstract][Full Text] [Related]
2. Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT2A receptor responsivity.
Bull EJ; Hutson PH; Fone KC
Neuropharmacology; 2004 Feb; 46(2):202-10. PubMed ID: 14680758
[TBL] [Abstract][Full Text] [Related]
3. Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity.
Fone KC; Beckett SR; Topham IA; Swettenham J; Ball M; Maddocks L
Psychopharmacology (Berl); 2002 Feb; 159(4):437-44. PubMed ID: 11823897
[TBL] [Abstract][Full Text] [Related]
4. Tolerance to 3,4-methylenedioxymethamphetamine is associated with impaired serotonin release.
Jones K; Brennan KA; Colussi-Mas J; Schenk S
Addict Biol; 2010 Jul; 15(3):289-98. PubMed ID: 20477756
[TBL] [Abstract][Full Text] [Related]
5. Effect of chronic m-CPP on locomotion, hypophagia, plasma corticosterone and 5-HT2C receptor levels in the rat.
Fone KC; Austin RH; Topham IA; Kennett GA; Punhani T
Br J Pharmacol; 1998 Apr; 123(8):1707-15. PubMed ID: 9605579
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats.
Walker QD; Williams CN; Jotwani RP; Waller ST; Francis R; Kuhn CM
Psychopharmacology (Berl); 2007 Jan; 189(4):435-45. PubMed ID: 17019566
[TBL] [Abstract][Full Text] [Related]
7. Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion.
Gurtman CG; Morley KC; Li KM; Hunt GE; McGregor IS
Eur J Pharmacol; 2002 Jun; 446(1-3):89-96. PubMed ID: 12098589
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors.
McCreary AC; Bankson MG; Cunningham KA
J Pharmacol Exp Ther; 1999 Sep; 290(3):965-73. PubMed ID: 10454466
[TBL] [Abstract][Full Text] [Related]
9. Behavioral and neurochemical effects of repeated MDMA administration during late adolescence in the rat.
Cox BM; Shah MM; Cichon T; Tancer ME; Galloway MP; Thomas DM; Perrine SA
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():229-35. PubMed ID: 24121061
[TBL] [Abstract][Full Text] [Related]
10. A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats.
Overstreet DH; Knapp DJ; Moy SS; Breese GR
Psychopharmacology (Berl); 2003 Jun; 167(4):344-52. PubMed ID: 12677355
[TBL] [Abstract][Full Text] [Related]
11. N-tert-butyl-alpha-phenylnitrone protects against 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats.
Yeh SY
Synapse; 1999 Mar; 31(3):169-77. PubMed ID: 10029234
[TBL] [Abstract][Full Text] [Related]
12. Administration of SCH 23390 into the medial prefrontal cortex blocks the expression of MDMA-induced behavioral sensitization in rats: an effect mediated by 5-HT2C receptor stimulation and not by D1 receptor blockade.
Ramos M; Goñi-Allo B; Aguirre N
Neuropsychopharmacology; 2005 Dec; 30(12):2180-91. PubMed ID: 15841107
[TBL] [Abstract][Full Text] [Related]
13. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
Colado MI; Williams JL; Green AR
Br J Pharmacol; 1995 Aug; 115(7):1281-9. PubMed ID: 7582557
[TBL] [Abstract][Full Text] [Related]
14. Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat.
O'Loinsigh ED; Boland G; Kelly JP; O'Boyle KM
Prog Neuropsychopharmacol Biol Psychiatry; 2001 Apr; 25(3):621-38. PubMed ID: 11371001
[TBL] [Abstract][Full Text] [Related]
15. 2-Deoxy-D-glucose prevents and nicotinamide potentiates 3, 4-methylenedioxymethamphetamine-induced serotonin neurotoxicity.
Hervías I; Lasheras B; Aguirre N
J Neurochem; 2000 Sep; 75(3):982-90. PubMed ID: 10936179
[TBL] [Abstract][Full Text] [Related]
16. A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field.
Mechan AO; Moran PM; Elliott M; Young AJ; Joseph MH; Green R
Psychopharmacology (Berl); 2002 Jan; 159(2):167-75. PubMed ID: 11862345
[TBL] [Abstract][Full Text] [Related]
17. Chronic treatment with a serotonin(2) receptor (5-HT(2)R) agonist modulates the behavioral and cellular response to (+)-3,4-methylenedioxymethamphetamine [(+)-MDMA].
Ross JD; Herin DV; Frankel PS; Thomas ML; Cunningham KA
Drug Alcohol Depend; 2006 Feb; 81(2):117-27. PubMed ID: 16054778
[TBL] [Abstract][Full Text] [Related]
18. Pre-treatment with 3,4-methylenedioxymethamphetamine (MDMA) causes long-lasting changes in 5-HT2A receptor-mediated glucose utilization in the rat brain.
Bull EJ; Porkess V; Rigby M; Hutson PH; Fone KC
J Psychopharmacol; 2006 Mar; 20(2):272-80. PubMed ID: 16510485
[TBL] [Abstract][Full Text] [Related]
19. Effect of 3,4-methylenedioxymethamphetamine on [3H]paroxetine binding in the frontal cortex and blood platelets of rats.
Nash JF; Arora RC; Schreiber MA; Meltzer HY
Biochem Pharmacol; 1991 Jan; 41(1):79-84. PubMed ID: 1702633
[TBL] [Abstract][Full Text] [Related]
20. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
McNamara R; Kerans A; O'Neill B; Harkin A
Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
